公司代码：688278 公司简称：特宝生物 厦门特宝生物工程股份有限公司 投资者关系活动记录表 ...

公司代码：688278 公司简称：特宝生物 厦门特宝生物工程股份有限公司 投资者关系活动记录表 （2023 年第三季度业绩说明会） 厦门特宝生物工程股份有限公司 投资者关系活动记录表 □公司现场接待 □电话接待 投资者关系活动 □其它场所接待 □公开说明会 类别 R定期报告说明会 □重要公告说明会 参与单位名称 全体投资者均可通过网络互动的方式参与本次说明会 ...

重要内容提示： 厦门特宝生物工程股份有限公司 投资者可于 2023 年 10 月 25 日（星期三）至 10 月 31 日（星期二） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （ir@amoytop.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 厦门特宝生物工程股份有限公司（以下简称"公司"）已于 2023 年 10 月 20 日在上海证券交易所披露了公司 2023 年第三季度报告，为便于广大投资者更全 面深入地了解公司 2023 年第三季度经营成果和财务状况，公司计划于 2023 年 11 月 1 日 13:00-14:00 举行 2023 年第三季度业绩说明会，就投资者关心的问题 进行交流。 一、说明会类型 证券代码：688278 证券简称：特宝生物 公告编号：2023-030 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四、投资者参加方式 （一）投资者可在 2023 年 11 月 1 日 13:00-14:0 ...

公司代码：688278 公司简称：特宝生物 厦门特宝生物工程股份有限公司 投资者关系活动记录表 ...

Financial Performance - The company's revenue for Q3 2023 reached ¥556,211,279.57, representing a year-over-year increase of 29.86%[3] - Net profit attributable to shareholders for Q3 2023 was ¥166,727,548.24, a significant increase of 149.78% compared to the same period last year[3] - The basic earnings per share for Q3 2023 was ¥0.41, reflecting a growth of 156.25% year-over-year[4] - Total operating revenue for the first three quarters of 2023 reached ¥1,459,790,700.44, an increase of 28.6% compared to ¥1,143,196,090.93 in the same period of 2022[20] - Net profit for the first three quarters of 2023 was ¥368,906,357.86, compared to ¥200,405,087.53 in 2022, representing an increase of 83.9%[22] - Basic earnings per share for the first three quarters of 2023 were ¥0.91, up from ¥0.49 in the same period of 2022[22] - The company reported a profit before tax of ¥447,671,911.13 for the first three quarters of 2023, compared to ¥267,093,136.16 in 2022, representing a growth of 67.5%[21] Research and Development - Research and development expenses totaled ¥71,692,245.17 in Q3 2023, accounting for 12.89% of revenue, a decrease of 2.83 percentage points from the previous year[4] - Research and development expenses for the first three quarters of 2023 totaled ¥142,861,485.40, an increase from ¥101,007,835.52 in 2022, marking a rise of 41.4%[20] Assets and Liabilities - Total assets as of the end of Q3 2023 amounted to ¥2,137,295,279.48, marking a 20.85% increase from the end of the previous year[4] - Total liabilities as of the end of the third quarter of 2023 amounted to ¥447,436,990.17, up from ¥360,959,315.86 at the end of 2022, reflecting a growth of 23.9%[18] - Total equity attributable to shareholders reached ¥1,689,858,289.31, compared to ¥1,407,600,331.45 in 2022, an increase of 20.0%[18] - The company reported a deferred income tax asset of $45,868,219.71, down from $47,415,013.66, a decrease of $1,546,793.95[26] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥382,951,697.45, reflecting a growth of 68.87%[4] - The net cash flow from operating activities for the first three quarters of 2023 was CNY 382,951,697.45, an increase of 68.9% compared to CNY 226,767,086.97 in the same period of 2022[23] - Total cash inflow from operating activities reached CNY 1,530,035,737.29, up from CNY 1,185,427,484.98, reflecting a growth of 29.0% year-over-year[23] - Cash outflow from operating activities was CNY 1,147,084,039.84, compared to CNY 958,660,398.01 in the previous year, marking an increase of 19.7%[23] Shareholder Information - The company has a total of 7,055 common shareholders as of the end of the reporting period[7] - The largest shareholder, Yang Ying, holds 33.94% of the shares, totaling 138,077,266 shares[7] Donations and Community Engagement - The company's cash donations for the "China Chronic Hepatitis B Clinical Cure (Everest) Project" amounted to RMB 5.25 million in the first nine months of 2023, with total donations reaching RMB 45 million[13] - The company has completed cash donations of RMB 1.1 million for the "China Chronic Hepatitis B Nucleoside Treatment Study (Unnamed) Project" as of the reporting period[13] - The company has donated a total of 100,000 doses of Peginterferon to various foundations, with 13,700 doses donated in 2023[13] Operational Management - The company plans to continue its market expansion and product development initiatives, although specific figures were not disclosed in the report[14] - The company's short-term borrowings and other liabilities were not specified, indicating a focus on operational cash flow management[17] Accounting Changes - The company has implemented new accounting standards starting January 1, 2023, affecting the financial statements[25]

证券代码：688278 证券简称：特宝生物 公告编号：2023-029 厦门特宝生物工程股份有限公司 关于实际控制人及其一致行动人自愿承诺 不减持公司股份的公告 二、承诺主体持股情况 截至本公告日，上述承诺主体直接持有公司股份情况如下： | 序号 | 股东名称 | 持股数量（股） | 持股比例 | 股份性质 | | | | --- | --- | --- | --- | --- | --- | --- | | 1 | 杨英 | 138,077,266 | 33.94% | 无限售条件流 | | | | 2 | 孙黎 | 32,539,237 | 8.00% | 通股，已于 | | 2023 | | | | | | 年 1 17 | 月 | 日上 | | 3 | 蔡智华 | 11,428,121 | 2.81% | 市流通。 | | | | | 合计 | 182,044, 624 | 44.75% | / | | | 公司董事会将对上述承诺的履行情况进行监督并及时履行信息披露义务。 特此公告。 厦门特宝生物工程股份有限公司 董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏 ...

国金证券股份有限公司 关于厦门特宝生物工程股份有限公司 2023年半年度持续督导跟踪报告 国金证券股份有限公司（以下简称"保荐机构"）作为厦门特宝生物工程 股份有限公司（以下简称"特宝生物"或"公司"）首次公开发行股票并在科 创板上市项目的保荐机构，根据《中华人民共和国证券法》《证券发行上市保 荐业务管理办法》《上海证券交易所科创板股票上市规则》等相关规定，负责 特宝生物上市后的持续督导工作，并出具2023年半年度持续督导跟踪报告。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针对具 | 保荐机构已建立并有效执行了 | | | | 持续督导制度，并制定了相应 | | | 体的持续督导工作制定相应的工作计划 | 的工作计划 | | 2 | 根据中国证监会相关规定，在持续督导工作开始前， 与上市公司或相关当事人签署持续督导协议，明确双 | 保荐机构已与特宝生物签订 | | | | 《持续督导协议》，该协议明 | | | 方在持续督导期间的权利义务，并报上海证券交易所 | 确了双方在持续督导期间的权 | | | 备案 | 利 ...

集体业绩说明会的公告 重要内容提示： 证券代码：688278 证券简称：特宝生物 公告编号：2023-027 关于参加2023 年半年度制药及生物制品行业 投资者可于 2023 年 9 月 6 日（星期三）16:00 前通过邮件、电话、传真 等形式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资 者普遍关注的问题进行回答。 厦门特宝生物工程股份有限公司（以下简称"公司"）已于 2023 年 8 月 18 日在上海证券交易所披露了公司 2023 年半年度报告，为便于广大投资者更全面 深入地了解公司 2023 年半年度经营成果、财务状况、发展理念，公司参与了由 上海证券交易所主办的 2023 年半年度制药及生物制品行业集体业绩说明会，此 次活动将采用视频和网络文字互动的方式举行，投资者可登录上海证券交易所上 证路演中心（http://roadshow.sseinfo.com/）参与线上互动交流。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司 四、联系人及咨询办法 一、说明会类型 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2023, representing a year-on-year increase of 20%[2]. - The company's operating revenue for the first half of 2023 reached ¥903,579,420.87, representing a year-on-year increase of 26.40% compared to ¥714,867,789.45 in the same period last year[18]. - Net profit attributable to shareholders for the same period was ¥202,178,809.62, up 51.27% from ¥133,654,117.58 in the previous year[18]. - The net profit after deducting non-recurring gains and losses increased by 54.36%, amounting to ¥232,982,206.21 compared to ¥150,937,683.00 last year[18]. - The basic earnings per share rose to ¥0.50, a 51.52% increase from ¥0.33 in the previous year[19]. - The total revenue for the reporting period is ¥1 billion, with a net profit of ¥647.69 million[48]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2023, representing a 25% year-over-year growth[102]. - The company reported a significant increase in revenue for the first half of 2023, with a year-on-year growth of 25%[109]. Research and Development - The company has allocated RMB 100 million for R&D in innovative drug development for the year 2023, focusing on enhancing drug efficacy and safety[2]. - The company achieved a total R&D investment of approximately ¥167.12 million, representing a 95.90% increase compared to the previous year[43]. - The R&D investment as a percentage of operating revenue was 18.50%, an increase of 6.57 percentage points from 11.93% in the previous year[19]. - Research and development expenses increased by 48.74% to CNY 77.21 million, indicating a strong commitment to new drug development[68]. - The company is actively developing new products, including Pegfilgrastim, which has a longer half-life and lower dosage compared to existing products, providing more treatment options for patients[24]. - The company has launched five products, including Pegbinterferon, which is the world's first 40kD PEGylated interferon α-2b injection, supported by multiple national science and technology projects[22]. - The company has received clinical trial approval for two new drugs and successfully launched one new drug during the reporting period[40]. - The company is expanding its R&D pipeline through collaborations, including a partnership with Aligos Therapeutics, Inc. for hepatitis treatment[57]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market penetration by the end of 2023[2]. - The company has initiated a strategic acquisition of a biotech firm, which is expected to enhance its R&D capabilities and product pipeline[2]. - The company is considering strategic acquisitions to bolster its market position, with a target of identifying two potential candidates by the end of the year[102]. - Market expansion plans include entering three new international markets by Q4 2023[102]. - The company has committed to maintaining a stable shareholding structure, with no major share reductions planned for the next 36 months[103]. Financial Position and Assets - The company's total assets at the end of the reporting period were ¥1,863,827,105.25, reflecting a 5.39% increase from ¥1,768,559,647.31 at the end of the previous year[18]. - The company's inventory rose by 18.11% to CNY 153.22 million, reflecting growth in business scale[70]. - The total liabilities decreased to ¥340,696,364.18 from ¥360,959,315.86, a reduction of about 5.6%[151]. - Shareholders' equity increased to RMB 1,523,130,741.07 from RMB 1,407,600,331.45, reflecting a growth of approximately 8.2%[151]. - The total assets of the company at the end of the reporting period are CNY 1,523,130,741.07, reflecting the company's financial position[166]. Compliance and Governance - The board of directors has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[6]. - The company has established a governance structure including a shareholders' meeting, board of directors, and supervisory board, ensuring effective management and oversight[174]. - The company is committed to maintaining transparency and accountability in its operations and financial disclosures[123]. - The company has not engaged in any violations regarding guarantees during the reporting period[125]. Environmental and Social Responsibility - The company has invested ¥107.30 million in environmental protection during the reporting period[83]. - The company is utilizing distributed photovoltaic power stations on building rooftops to improve energy efficiency and reduce carbon emissions[93]. - The company has engaged in a public welfare project aimed at enhancing liver disease prevention and control in rural areas, screening over 20,000 individuals by July 2023[94]. - The company has implemented a self-monitoring plan for environmental compliance, with regular monitoring results meeting standards[88]. Risks and Challenges - The company has identified potential risks in its operations, including regulatory changes and market competition, and has outlined mitigation strategies in its report[4]. - The company is facing risks related to technological upgrades and potential patent issues that could impact its core competitiveness[59][60]. - The company is committed to addressing the high risks associated with drug development, including potential clinical research failures and regulatory changes[60].

证券代码：688278 证券简称：特宝生物 公告编号：2023-024 监事会在全面审阅公司 2023 年半年度报告及其摘要后，发表意见如下： 1、公司 2023 年半年度报告及其摘要的内容真实、客观地反映了 2023 年半 年度的财务状况和经营成果。 2、公司 2023 年半年度报告及其摘要的编制和审议程序符合中国证券监督 管理委员会、上海证券交易所颁布的有关法律法规、规范性文件以及公司内部 管理制度的各项规定。报告编制过程中，未发现参与报告编制和审议的人员有 违反保密规定的行为。 厦门特宝生物工程股份有限公司 第八届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 厦门特宝生物工程股份有限公司（以下简称"公司"）第八届监事会第九 次会议于 2023 年 8 月 17 日以现场结合通讯表决的方式召开。本次会议已于 2023 年 8 月 4 日以邮件方式通知了全体监事，本次会议由监事会主席刘军先生 主持，会议应到监事 3 人，实到监事 3 人。本次会议的召开符合《公司法》及 ...